You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Commensal Intestinal Protozoa - Pathogenic Commensal or Beneficial?: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Lindsay Dong and Version 1 by Jesper Bonnet Moeller.

The human gastrointestinal microbiota contains a diverse consortium of microbes, including bacteria, protozoa, viruses, and fungi. Through millennia of co-evolution, the host–microbiota interactions have shaped the immune system to both tolerate and maintain the symbiotic relationship with commensal microbiota, while exerting protective responses against invading pathogens. Microbiome research is dominated by studies describing the impact of prokaryotic bacteria on gut immunity with a limited understanding of their relationship with other integral microbiota constituents. However, converging evidence shows that eukaryotic organisms, such as commensal protozoa, can play an important role in modulating intestinal immune responses as well as influencing the overall health of the host. The presence of several protozoa species has recently been shown to be a common occurrence in healthy populations worldwide, suggesting that many of these are commensals rather than invading pathogens. 

  • bacteria
  • Blastocystis
  • Dientamoeba
  • Entamoeba
  • gut immunity
  • intestinal protozoa
  • microbiota

1. Introduction

The mammalian gut harbors a vast number of viruses, bacteria, fungi, and protozoa (single-celled eukaryotes), collectively referred to as the microbiota [1]. Dynamic interplay between these distinct microbiota constituents and the host contributes to many essential physiological processes, including development, metabolism, and immunity [2,3][2][3]. It is becoming increasingly evident that disruption of this complex ecosystem, referred to as gut dysbiosis, contributes to the development of various gastrointestinal as well as systemic diseases, such as inflammatory bowel disease (IBD), metabolic disorder, autoimmunity, and cancer [4,5,6][4][5][6]. Furthermore, emerging evidence of a bidirectional crosstalk between the intestinal microbiota and the brain has linked dysbiosis to various diseases of the central nervous system, such as depression, multiple sclerosis, and Parkinson’s disease [7,8][7][8]. It is well recognized that the intestinal microbiota plays a pivotal role in the manifestations of IBD [9]. IBD is a chronic inflammatory disease of the intestinal lining that can be classified into two distinct conditions, Crohn’s disease or ulcerative colitis [10]. Although usually not fatal, IBD is associated with lowered life expectancy and significantly decreased quality of life for patients that suffer from chronic symptoms, including persistent diarrhea, abdominal pain, and rectal bleeding. Moreover, chronic inflammation in IBD has been associated with serious, often fatal comorbidities, including cancer, cardiovascular diseases, and liver diseases [11,12][11][12]. The rate of incidence of IBD has been rising dramatically since the industrial revolution, with a current global burden of more than 6 million people [13]. Although the IBD etiology remains largely unknown, it has been hypothesized that the industrial lifestyle, which includes increased use of antibiotics and a diet rich in highly processed foods, has resulted in detrimental changes to the intestinal microbiota that significantly contribute to disease risk [9,14][9][14]. Therefore, a detailed understanding of the biological roles of distinct intestinal microbial groups, their mutual interactions, as well as their impact on human disease is of paramount importance.
Since most studies have concentrated on gut-resident bacteria as the main component of the microbiota, the mechanisms and consequences of intestinal protozoa colonization have only recently begun to be clarified [3,15,16,17][3][15][16][17]. Protozoa are a diverse group of single-celled eukaryotic organisms that can be found in a variety of environments either as free-living or parasitic/symbiotic microbes. Historically, protozoa have been classified into four subgroups: amoebas, flagellates, coccidians, and ciliates, and their categorization depends on specific morphological features, such as internal structure and motility [18]. After the emergence of molecular phylogenetics, an updated classification has been proposed, integrating insights from the genomic studies with the structural and biochemical evidence. Thus, protozoa have been proposed to comprise two subkingdoms, with Choanozoa and Amoebozoa grouped together as the subkingdom Sarcomastigota, while Alveolata, Rhizaria, Excavata, and Apusozoa constitute the subkingdom Biciliata [19]. More recently, an even more updated classification has been proposed [20]. From an evolutionary point of view, eukaryotic microbes such as protozoa have co-evolved with humans and undoubtedly affected the dynamics of the gut microbiota [21]. Despite extensive strides in parasitic research, including studies of pathogenic protozoa, the role of commensal protozoa in shaping the immune landscape of the gut remains enigmatic and questioned [22,23,24][22][23][24]. One of the main challenges lies in the characteristic features and biological classification of commensal protozoa [25]. By definition, commensal microbes reside within the host without causing a negative health impact and are well tolerated by the immune system [26]. However, due to the highly dynamic nature of the host–microbiota interactions, a particular protozoa can be classified as commensal rather than parasitic, and vice-versa, often in a context-specific manner [21,27,28][21][27][28]. Furthermore, heterogeneity in experimental design, differences between protozoa species, and geographical changes in gut microbiota all result in a lack of consensus regarding the exact role of intestinal protozoa and their contribution to mucosal immune homeostasis [15,29][15][29]. It is well established that the bacterial compartment of human gut microbiota comprises a plethora of different species, ranging from beneficial to opportunistic and/or pathogenic [30].

2. Intestinal Protozoa—Pathogenic, Commensal, or Beneficial?

2.1. Blastocystis spp.

Blastocystis spp. is one of the most prevalent protozoa found in humans, with an estimated 1 billion colonized individuals worldwide [22,40][22][31]. Historically, Blastocystis was predominantly characterized as a parasitic protozoa [53][32], but conflicting results regarding its pathogenic potential and clinical significance have emerged in several studies [40][31]. Blastocystis has been associated with the etiology of irritable bowel syndrome (IBS) [54,55,56,57][33][34][35][36] and IBD [58][37]. In contrast, other cohort studies have found no correlation between gastrointestinal symptoms and the presence of Blastocystis, either in healthy subjects or IBS patients [59,60][38][39]. Similarly, the prevalence of Blastocystis infection has been inconsistently reported to be higher in either immunocompetent or immunocompromised individuals depending on the study [61,62][40][41]. One possible explanation for this discrepancy is that Blastocystis has mainly been investigated as a causative agent in disease propagation, with limited information about its distribution in a healthy population. With recent advances in sequencing technologies and an increased number of epidemiological surveys, it has become evident that the presence of Blastocystis is a common occurrence in both healthy and symptomatic individuals, which inevitably questions its alleged pathogenicity [63,64][42][43]. To date, at least 17 Blastocystis subtypes (ST) have been identified, of which nine are found in humans (ST1-ST9), with ST1–ST4 accounting for up to 90% of all occurrences [40,65][31][44]. At the other end of the spectrum, beneficial roles for Blastocystis have also been proposed. Colonization with Blastocystis is associated with higher microbial diversity and richness, both of which are suggested to benefit intestinal health [22,70][22][45]. Additionally, it has been shown that body mass index is strongly negatively correlated with Blastocystis presence [71][46]. Several studies have reported that colonization with Blastocystis is more common in healthy subjects than in patients with active IBD, IBS, or CRC, supporting that Blastocystis might be considered a component of the healthy intestinal microbiota [58,60,71,72,73][37][39][46][47][48].

2.2. Dientamoeba fragilis

Like Blastocystis spp., colonization with Dientamoeba fragilis has been reported to exert conflicting roles in gut homeostasis. In contrast to other intestinal protozoa whose colonization prevalence is generally considered higher in the emerging nations, D. fragilis has been identified more frequently in the developed world [78,79][49][50]. However, due to differences in surveillance systems and diagnostic procedures, its prevalence might be underestimated in some regions [78][49]. The presence of D. fragilis has frequently been associated with disease [45][51], just as it has been commonly found in asymptomatic carriers [72,73,74][47][48][52].

2.3. Entamoeba spp.

Other common intestinal inhabitants with a worldwide distribution are Entamoeba species, the majority of which are generally accepted as commensal organisms [83][53]. Currently, eight species have been identified that are able to infect humans: E. histolytica, E. bangladeshi, E. dispar, E. hartmanni, E. moshkovskii, E. coli, and E. polecki, with E. histolytica as the only one with well-established pathogenicity [84][54]. The worldwide frequency of Entamoeba occurrence in humans is estimated at 3.5%. However, the prevalence of commensal Entamoeba spp. has largely been underestimated due to high morphological and genetic similarity with the invasive E. histolytica [83,84][53][54]. Microscopy, the most widely used method for the detection of Entamoeba organisms, is not always sufficient for differentiating between the invasive E. histolytica and non-pathogenic strains of Entamoeba [85][55]. Increased use of molecular diagnostic methods has recently revealed that colonization with commensal Entamoeba spp. is overall more common than infections with E. histolytica [85][55].

3. Protozoa–Microbiota Interactions

The various communities of intestinal bacteria play a fundamental role in determining human health. It is generally suggested that high intestinal microbial diversity is a hallmark of a healthy and resilient gut microbiota [91][56]. Emerging studies consistently report increased bacterial diversity as well as community compositional changes evident in protozoa-colonized individuals (Table 2) [21,22,70,87][21][22][45][57]. Among the characteristic features of Blastocystis colonization is a higher abundance of specific taxa within Firmicutes, especially those from the Clostridia class, such as Ruminococcaceae and Prevotellaceae families, and a general decrease of Bacteroides abundance [71,74,92][46][52][58]. Furthermore, Blastocystis carriers show a significant decrease of Enterobacteriaceae and Proteobacteria when compared to Blastocystis-free subjects [70,71][45][46]. Interestingly, Proteobacteria and several species within the Enterobacteriaceae family can be considered “pathogenic” and linked to microbial dysbiosis associated with the development and pathogenesis of IBD [93,94,95][59][60][61]. Moreover, the presence of Blastocystis is strongly associated with the abundance of archaeal organisms, primarily Methanobrevibacter smithii [70,71,74][45][46][52]. M. smithii has been shown to play an important role in human health, supporting the digestion of glycans through the removal of bacterial fermentation end products [96][62]. M. smithii, together with members of the Faecalibacterium and Roseburia genera that are also enriched in Blastocystis-colonized individuals [22[22][45],70], increase the production of the short-chain fatty acid butyrate [97][63]. Butyrate has well-established beneficial effects on gut health, serving as an important energy source for colonic epithelial cells and acting as an inhibitor of gut inflammation [97,98][63][64]. Butyrate-producing bacteria, specifically Faecalibacterium prausnitzii and Roseburia spp., appear to be significantly reduced in patients with Crohn’s disease and have emerged as potential therapeutics for IBD [97,99,100][63][65][66]. On the other hand, adverse associations between Blastocystis colonization and eubiotic microbial profile have also been described. Several studies have reported a decrease of Bifidobacterium in individuals colonized with Blastocystis [70,101][45][67]. Bifidobacterium spp. have been associated with homeostatic functions within the gut, including protection of the epithelial barrier and regulation of inflammation [102][68]. Accordingly, a study by Alzate et al. showed that children colonized with Blastocystis exhibited markedly reduced abundance of the highly beneficial Akkermansia spp. compared to children that were Blastocystis-free [48][69]. Research on microbiota composition associated with D. fragilis colonization is limited. However, a study conducted in Denmark investigating the microbial profile in D. fragilis-positive children revealed 16 bacterial genera that were significantly more abundant in colonized children [82][70]. Some of the most enriched bacterial genera in D. fragilis carriers were Victivallis, Oscillibacter and Coprococcus, whereas Flavonifractor was enriched in non-colonized children. After the removal of D. fragilis by metronidazole treatment, the abundance of Flavonifractor increased while other bacteria, such as Coproccocus, were reduced in previously colonized children that were cleared of D. fragilis. Evaluating microbiota composition after metronidazole treatment should be done cautiously since this drug is effective against most anaerobic bacteria [106][71]. Colonization with Entamoeba spp. results in increased microbiota diversity and compositional changes, characterized by an increase of Firmicutes taxa, such as Ruminococcaceae, coupled with a significant decrease of Bacteroides [21,86][21][72]. Interestingly, a reduced ratio of Firmicutes to Bacteroides causes loss of microbial diversity as well as dysbiosis linked to the progression of IBD, CRC, and type 2 diabetes [109,110][73][74].  Together, commensal gut protozoa significantly remodel the intestinal bacterial niche, potentially creating a favorable microenvironment beneficial for the host. A common observation across the different protozoa species seems to be an enrichment of SCFA-producing bacteria. Importantly, this is in contrast to what has been demonstrated for pathogenic protozoa, e.g., Cryptosporidium, where increased infection severity corresponded with a decreased level of fecal SCFA content [113][75].

4. The Impact of Commensal Gut Protozoa on the Host Immune System

Recently, it was shown that colonization with Blastocystis ST4 attenuates colonic inflammation in a dextran sulfate sodium (DSS)-induced colitis mouse model via induction of T helper (Th) 2 cells and T regulatory (Treg) cells [76]. Mice colonized with Blastocystis ST4 showed a decrease of tumor necrosis factor-α expressing (TNF) CD4+ T-cells and an upregulation of signature Th2 cytokines interleukin (IL)-4, IL-5, and IL-13, as well as the anti-inflammatory cytokine IL-10 [76]. Additionally, a marked increase of abundance of SCFA-producing bacteria, such as Ruminococcaceae and Roseburia, was observed following Blastocystis ST4 colonization. Analysis of the SCFA content in feces from colitic mice that had received fecal matter transplant from Blastocystis ST4-colonized mice revealed enrichment of 6 SCFAs (butyric, isobutyric, valeric, isovaleric, 2-methylbutyric, and caproic acid) compared to mice that received fecal matter transplant from Blastocystis-free mice [76]. Importantly, recent reports have repeatedly suggested a highly beneficial role of SCFAs on gut homeostasis and immune modulation [129][77]. SCFAs in the intestinal lumen are absorbed by colonocytes where they enter the citric acid cycle and are used for energy production. Unmetabolized SCFAs enter the systemic circulation and travel to different organs, serving as substrates or signaling molecules for various cellular processes such as chemotaxis, proliferation, and differentiation [130,131][78][79]. SCFAs achieve this by acting as histone deacetylase (HDAC) inhibitors as well as activators of cell surface receptors [130][78]. It has been demonstrated that butyrate, created by SCFA-producing microorganisms in the intestines, can facilitate generation of extrathymic Tregs via enhanced acetylation of Foxp3 locus in CD4+ T cells. 

On the other hand, Blastocystis ST7 has been suggested to have immunocompromising functions, and several potential virulence factors have been identified that could support the notion of pathogenicity. Antigens from Blastocystis ST7 have been reported to induce the mitogen-activated protein kinase-dependent expression of pro-inflammatory cytokines such as IL-1β, IL-6, and tumor necrosis factor, in macrophages, mouse intestinal explants, and colonic tissue [134][80]. Furthermore, Blastocystis ST7 has a significantly higher activity of cysteine proteases compared to other Blastocystis subtypes. Cysteine proteases are a characteristic feature of parasitic protozoa (e.g., Entamoeba histolytica and Cryptosporidium spp.) that have been shown to facilitate invasion of host tissue, as well as immune evasion [135][81].

5. Conclusions

Intestinal protozoa have co-evolved with humans, and their interactions with the human host seem to be highly dynamic and variable, with some species and subtypes exhibiting beneficial properties, while others manifest adverse immunomodulatory effects. The fact that many of these protozoa species cause dormant persistent colonization that often leads to life-long affiliation with their host, points towards commensalism or even symbiosis rather than parasitism. In line with that, colonization with intestinal protozoa appears to significantly increase the diversity of the gut microbiota and selectively modulate the composition of different bacterial communities. Some outstanding questions remain as to whether a therapeutic impact might be achieved by diversification of the human gut via controlled colonization with commensal protozoa strains or by FMT from protozoa-colonized healthy donors to patients with IBD or other gastrointestinal diseases. FMT is an emerging therapy with a successful track record against severe intestinal bacterial infections and a potential therapeutic candidate against diseases associated with microbial dysbiosis [140][82].

References

  1. Kho, Z.Y.; Lal, S.K. The Human Gut Microbiome—A Potential Controller of Wellness and Disease. Front. Microbiol. 2018, 9, 1835.
  2. Xiong, J.; Hu, H.; Xu, C.; Yin, J.; Liu, M.; Zhang, L.; Duan, Y.; Huang, Y. Development of gut microbiota along with its metabolites of preschool children. BMC Pediatr. 2022, 22, 25.
  3. Clemente, J.C.; Ursell, L.K.; Parfrey, L.W.; Knight, R. The impact of the gut microbiota on human health: An integrative view. Cell 2012, 148, 1258–1270.
  4. Maeda, Y.; Takeda, K. Host-microbiota interactions in rheumatoid arthritis. Exp. Mol. Med. 2019, 51, 1–6.
  5. Gopalakrishnan, V.; Helmink, B.A.; Spencer, C.N.; Reuben, A.; Wargo, J.A. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer Cell 2018, 33, 570–580.
  6. Zhang, M.; Sun, K.; Wu, Y.; Yang, Y.; Tso, P.; Wu, Z. Interactions between Intestinal Microbiota and Host Immune Response in Inflammatory Bowel Disease. Front. Immunol. 2017, 8, 942.
  7. Rogers, G.B.; Keating, D.J.; Young, R.L.; Wong, M.L.; Licinio, J.; Wesselingh, S. From gut dysbiosis to altered brain function and mental illness: Mechanisms and pathways. Mol. Psychiatry 2016, 21, 738–748.
  8. Maiuolo, J.; Gliozzi, M.; Musolino, V.; Carresi, C.; Scarano, F.; Nucera, S.; Scicchitano, M.; Oppedisano, F.; Bosco, F.; Ruga, S.; et al. The Contribution of Gut Microbiota-Brain Axis in the Development of Brain Disorders. Front. Neurosci. 2021, 15, 616883.
  9. Caruso, R.; Lo, B.C.; Núñez, G. Host-microbiota interactions in inflammatory bowel disease. Nat. Rev. Immunol. 2020, 20, 411–426.
  10. García, M.J.; Pascual, M.; Del Pozo, C.; Díaz-González, A.; Castro, B.; Rasines, L.; Crespo, J.; Rivero, M. Impact of immune-mediated diseases in inflammatory bowel disease and implications in therapeutic approach. Sci. Rep. 2020, 10, 10731.
  11. Argollo, M.; Gilardi, D.; Peyrin-Biroulet, C.; Chabot, J.F.; Peyrin-Biroulet, L.; Danese, S. Comorbidities in inflammatory bowel disease: A call for action. Lancet Gastroenterol. Hepatol. 2019, 4, 643–654.
  12. Matos, R.; Lencastre, L.; Rocha, V.; Torres, S.; Vieira, F.; Barbosa, M.R.; Ascenção, J.; Guerra, M.P. Quality of life in patients with inflammatory bowel disease: The role of positive psychological factors. Health Psychol. Behav. Med. 2021, 9, 989–1005.
  13. Silangcruz, K.; Nishimura, Y.; Czech, T.; Kimura, N.; Hagiya, H.; Koyama, T.; Otsuka, F. Impact of the World Inflammatory Bowel Disease Day and Crohn’s and Colitis Awareness Week on Population Interest Between 2016 and 2020: Google Trends Analysis. JMIR Infodemiol. 2021, 1, e32856.
  14. Cui, G.; Liu, H.; Xu, G.; Laugsand, J.B.; Pang, Z. Exploring Links Between Industrialization, Urbanization, and Chinese Inflammatory Bowel Disease. Front. Med. 2021, 8, 757025.
  15. Lukeš, J.; Stensvold, C.R.; Jirků-Pomajbíková, K.; Wegener Parfrey, L. Are Human Intestinal Eukaryotes Beneficial or Commensals? PLoS Pathog. 2015, 11, e1005039.
  16. Chudnovskiy, A.; Mortha, A.; Kana, V.; Kennard, A.; Ramirez, J.D.; Rahman, A.; Remark, R.; Mogno, I.; Ng, R.; Gnjatic, S.; et al. Host-Protozoan Interactions Protect from Mucosal Infections through Activation of the Inflammasome. Cell 2016, 167, 444–456.e414.
  17. Wei, Y.; Gao, J.; Kou, Y.; Meng, L.; Zheng, X.; Liang, M.; Sun, H.; Liu, Z.; Wang, Y. Commensal Bacteria Impact a Protozoan’s Integration into the Murine Gut Microbiota in a Dietary Nutrient-Dependent Manner. Appl. Environ. Microbiol. 2020, 86, e00303-20.
  18. Issa, R. Non-pathogenic protozoa. Int. J. Pharm. Pharm. Sci. 2014, 6, 30–40.
  19. Cavalier-Smith, T. Protist phylogeny and the high-level classification of Protozoa. Eur. J. Protistol. 2003, 39, 338–348.
  20. Ocaña, K.A.; Dávila, A.M. Phylogenomics-based reconstruction of protozoan species tree. Evol. Bioinform. Online 2011, 7, 107–121.
  21. Even, G.; Lokmer, A.; Rodrigues, J.; Audebert, C.; Viscogliosi, E.; Ségurel, L.; Chabé, M. Changes in the Human Gut Microbiota Associated With Colonization by Blastocystis sp. and Entamoeba spp. in Non-Industrialized Populations. Front. Cell. Infect. Microbiol. 2021, 11, 533528.
  22. Audebert, C.; Even, G.; Cian, A.; Safadi, D.E.; Certad, G.; Delhaes, L.; Pereira, B.; Nourrisson, C.; Poirier, P.; Wawrzyniak, I.; et al. Colonization with the enteric protozoa Blastocystis is associated with increased diversity of human gut bacterial microbiota. Sci. Rep. 2016, 6, 25255.
  23. von Huth, S.; Thingholm, L.B.; Kofoed, P.-E.; Bang, C.; Rühlemann, M.C.; Franke, A.; Holmskov, U. Intestinal protozoan infections shape fecal bacterial microbiota in children from Guinea-Bissau. PLoS Negl. Trop. Dis. 2021, 15, e0009232.
  24. Chabé, M.; Lokmer, A.; Ségurel, L. Gut Protozoa: Friends or Foes of the Human Gut Microbiota? Trends Parasitol. 2017, 33, 925–934.
  25. Maritz, J.M.; Land, K.M.; Carlton, J.M.; Hirt, R.P. What is the importance of zoonotic trichomonads for human health? Trends Parasitol. 2014, 30, 333–341.
  26. Zheng, D.; Liwinski, T.; Elinav, E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020, 30, 492–506.
  27. Deng, L.; Wojciech, L.; Gascoigne, N.R.J.; Peng, G.; Tan, K.S.W. New insights into the interactions between Blastocystis, the gut microbiota, and host immunity. PLoS Pathog. 2021, 17, e1009253.
  28. Wawrzyniak, I.; Poirier, P.; Viscogliosi, E.; Dionigia, M.; Texier, C.; Delbac, F.; Alaoui, H.E. Blastocystis, an unrecognized parasite: An overview of pathogenesis and diagnosis. Ther. Adv. Infect. Dis. 2013, 1, 167–178.
  29. Leung, J.M.; Graham, A.L.; Knowles, S.C.L. Parasite-Microbiota Interactions With the Vertebrate Gut: Synthesis Through an Ecological Lens. Front. Microbiol. 2018, 9, 843.
  30. Panthee, B.; Gyawali, S.; Panthee, P.; Techato, K. Environmental and Human Microbiome for Health. Life 2022, 12, 456.
  31. Andersen, L.O.B.; Stensvold, C.R. Blastocystis in Health and Disease: Are We Moving from a Clinical to a Public Health Perspective? J. Clin. Microbiol. 2016, 54, 524–528.
  32. Stensvold, C.R.; van der Giezen, M. Associations between Gut Microbiota and Common Luminal Intestinal Parasites. Trends Parasitol. 2018, 34, 369–377.
  33. Nourrisson, C.; Scanzi, J.; Pereira, B.; NkoudMongo, C.; Wawrzyniak, I.; Cian, A.; Viscogliosi, E.; Livrelli, V.; Delbac, F.; Dapoigny, M.; et al. Blastocystis is associated with decrease of fecal microbiota protective bacteria: Comparative analysis between patients with irritable bowel syndrome and control subjects. PLoS ONE 2014, 9, e111868.
  34. Poirier, P.; Wawrzyniak, I.; Vivarès, C.P.; Delbac, F.; El Alaoui, H. New insights into Blastocystis spp.: A potential link with irritable bowel syndrome. PLoS Pathog. 2012, 8, e1002545.
  35. Shafiei, Z.; Esfandiari, F.; Sarkari, B.; Rezaei, Z.; Fatahi, M.R.; Hosseini Asl, S.M.K. Parasitic infections in irritable bowel syndrome patients: Evidence to propose a possible link, based on a case-control study in the south of Iran. BMC Res. Notes 2020, 13, 264.
  36. Kosik-Bogacka, D.; Lepczyńska, M.; Kot, K.; Szkup, M.; Łanocha-Arendarczyk, N.; Dzika, E.; Grochans, E. Prevalence, subtypes and risk factors of Blastocystis spp. infection among pre- and perimenopausal women. BMC Infect. Dis. 2021, 21, 1125.
  37. Petersen, A.M.; Stensvold, C.R.; Mirsepasi, H.; Engberg, J.; Friis-Møller, A.; Porsbo, L.J.; Hammerum, A.M.; Nordgaard-Lassen, I.; Nielsen, H.V.; Krogfelt, K.A. Active ulcerative colitis associated with low prevalence of Blastocystis and Dientamoeba fragilis infection. Scand. J. Gastroenterol. 2013, 48, 638–639.
  38. Leder, K.; Hellard, M.E.; Sinclair, M.I.; Fairley, C.K.; Wolfe, R. No correlation between clinical symptoms and Blastocystis hominis in immunocompetent individuals. J. Gastroenterol. Hepatol. 2005, 20, 1390–1394.
  39. Krogsgaard, L.R.; Engsbro, A.L.; Stensvold, C.R.; Nielsen, H.V.; Bytzer, P. The prevalence of intestinal parasites is not greater among individuals with irritable bowel syndrome: A population-based case-control study. Clin. Gastroenterol. Hepatol. 2015, 13, 507–513.e502.
  40. Gassama, A.; Sow, P.S.; Fall, F.; Camara, P.; Guèye-N’diaye, A.; Seng, R.; Samb, B.; M’Boup, S.; Aïdara-Kane, A. Ordinary and opportunistic enteropathogens associated with diarrhea in Senegalese adults in relation to human immunodeficiency virus serostatus. Int. J. Infect. Dis. 2001, 5, 192–198.
  41. Sarzhanov, F.; Dogruman-Al, F.; Santin, M.; Maloney, J.G.; Gureser, A.S.; Karasartova, D.; Taylan-Ozkan, A. Investigation of neglected protists Blastocystis sp. and Dientamoeba fragilis in immunocompetent and immunodeficient diarrheal patients using both conventional and molecular methods. PLoS Negl. Trop. Dis. 2021, 15, e0009779.
  42. Ramírez, J.D.; Sánchez, L.V.; Bautista, D.C.; Corredor, A.F.; Flórez, A.C.; Stensvold, C.R. Blastocystis subtypes detected in humans and animals from Colombia. Infect. Genet. Evol. 2014, 22, 223–228.
  43. Scanlan, P.D.; Stensvold, C.R.; Rajilić-Stojanović, M.; Heilig, H.G.; De Vos, W.M.; O’Toole, P.W.; Cotter, P.D. The microbial eukaryote Blastocystis is a prevalent and diverse member of the healthy human gut microbiota. FEMS Microbiol. Ecol. 2014, 90, 326–330.
  44. Sulżyc-Bielicka, V.; Kołodziejczyk, L.; Adamska, M.; Skotarczak, B.; Jaczewska, S.; Safranow, K.; Bielicki, P.; Kładny, J.; Bielicki, D. Colorectal cancer and Blastocystis sp. infection. Parasit. Vectors 2021, 14, 200.
  45. Kodio, A.; Coulibaly, D.; Koné, A.K.; Konaté, S.; Doumbo, S.; Guindo, A.; Bittar, F.; Gouriet, F.; Raoult, D.; Thera, M.A.; et al. Blastocystis Colonization Is Associated with Increased Diversity and Altered Gut Bacterial Communities in Healthy Malian Children. Microorganisms 2019, 7, 649.
  46. Beghini, F.; Pasolli, E.; Truong, T.D.; Putignani, L.; Cacciò, S.M.; Segata, N. Large-scale comparative metagenomics of Blastocystis, a common member of the human gut microbiome. ISME J. 2017, 11, 2848–2863.
  47. Rossen, N.G.; Bart, A.; Verhaar, N.; van Nood, E.; Kootte, R.; de Groot, P.F.; D’Haens, G.R.; Ponsioen, C.Y.; van Gool, T. Low prevalence of Blastocystis sp. in active ulcerative colitis patients. Eur. J. Clin. Microbiol. Infect. Dis. 2015, 34, 1039–1044.
  48. Krogsgaard, L.R.; Andersen, L.O.B.; Johannesen, T.B.; Engsbro, A.L.; Stensvold, C.R.; Nielsen, H.V.; Bytzer, P. Characteristics of the bacterial microbiome in association with common intestinal parasites in irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 2018, 9, e161.
  49. Cacciò, S.M. Molecular epidemiology of Dientamoeba fragilis. Acta Trop. 2018, 184, 73–77.
  50. Röser, D.; Simonsen, J.; Nielsen, H.V.; Stensvold, C.R.; Mølbak, K. Dientamoeba fragilis in Denmark: Epidemiological experience derived from four years of routine real-time PCR. Eur. J. Clin. Microbiol. 2013, 32, 1303–1310.
  51. Stark, D.; Barratt, J.; Chan, D.; Ellis, J.T. Dientamoeba fragilis, the Neglected Trichomonad of the Human Bowel. Clin. Microbiol. Rev. 2016, 29, 553–580.
  52. Tito, R.Y.; Chaffron, S.; Caenepeel, C.; Lima-Mendez, G.; Wang, J.; Vieira-Silva, S.; Falony, G.; Hildebrand, F.; Darzi, Y.; Rymenans, L.; et al. Population-level analysis of Blastocystis subtype prevalence and variation in the human gut microbiota. Gut 2019, 68, 1180–1189.
  53. López, M.C.; León, C.M.; Fonseca, J.; Reyes, P.; Moncada, L.; Olivera, M.J.; Ramírez, J.D. Molecular Epidemiology of Entamoeba: First Description of Entamoeba moshkovskii in a Rural Area from Central Colombia. PLoS ONE 2015, 10, e0140302.
  54. El-Dib, N.A.; Khater, M.M. Entamoeba. In Encyclopedia of Infection and Immunity; Rezaei, N., Ed.; Elsevier: Oxford, UK, 2022; pp. 492–512.
  55. Cui, Z.; Li, J.; Chen, Y.; Zhang, L. Molecular epidemiology, evolution, and phylogeny of Entamoeba spp. Infect. Genet. Evol. 2019, 75, 104018.
  56. Vieira-Silva, S.; Falony, G.; Darzi, Y.; Lima-Mendez, G.; Garcia Yunta, R.; Okuda, S.; Vandeputte, D.; Valles-Colomer, M.; Hildebrand, F.; Chaffron, S.; et al. Species–function relationships shape ecological properties of the human gut microbiome. Nat. Microbiol. 2016, 1, 16088.
  57. Valerio, I.; Floriana, S.; Valentina, T.; Fabrizio, P.; Anatole, M.; Veronica Di, C.; David Di, C.; Serena, S.; Federica, B.; Rossella, D.A. Gut microbiota related to Giardia duodenalis, Entamoeba spp. and Blastocystis hominis infections in humans from Côte d’Ivoire. J. Infect. Dev. Ctries. 2016, 10, 8179.
  58. O’Brien Andersen, L.; Karim, A.B.; Roager, H.M.; Vigsnæs, L.K.; Krogfelt, K.A.; Licht, T.R.; Stensvold, C.R. Associations between common intestinal parasites and bacteria in humans as revealed by qPCR. Eur. J. Clin. Microbiol. 2016, 35, 1427–1431.
  59. Baldelli, V.; Scaldaferri, F.; Putignani, L.; Del Chierico, F. The Role of Enterobacteriaceae in Gut Microbiota Dysbiosis in Inflammatory Bowel Diseases. Microorganisms 2021, 9, 697.
  60. Shin, N.-R.; Whon, T.W.; Bae, J.-W. Proteobacteria: Microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 2015, 33, 496–503.
  61. Vester-Andersen, M.K.; Mirsepasi-Lauridsen, H.C.; Prosberg, M.V.; Mortensen, C.O.; Träger, C.; Skovsen, K.; Thorkilgaard, T.; Nøjgaard, C.; Vind, I.; Krogfelt, K.A.; et al. Increased abundance of proteobacteria in aggressive Crohn’s disease seven years after diagnosis. Sci. Rep. 2019, 9, 13473.
  62. Camara, A.; Konate, S.; Tidjani Alou, M.; Kodio, A.; Togo, A.H.; Cortaredona, S.; Henrissat, B.; Thera, M.A.; Doumbo, O.K.; Raoult, D.; et al. Clinical evidence of the role of Methanobrevibacter smithii in severe acute malnutrition. Sci. Rep. 2021, 11, 5426.
  63. Geirnaert, A.; Calatayud, M.; Grootaert, C.; Laukens, D.; Devriese, S.; Smagghe, G.; De Vos, M.; Boon, N.; Van de Wiele, T. Butyrate-producing bacteria supplemented in vitro to Crohn’s disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity. Sci. Rep. 2017, 7, 11450.
  64. Hamer, H.M.; Jonkers, D.; Venema, K.; Vanhoutvin, S.; Troost, F.J.; Brummer, R.J. Review article: The role of butyrate on colonic function. Aliment. Pharmacol. Ther. 2008, 27, 104–119.
  65. Tong, M.; Li, X.; Wegener Parfrey, L.; Roth, B.; Ippoliti, A.; Wei, B.; Borneman, J.; McGovern, D.P.B.; Frank, D.N.; Li, E.; et al. A Modular Organization of the Human Intestinal Mucosal Microbiota and Its Association with Inflammatory Bowel Disease. PLoS ONE 2013, 8, e80702.
  66. Sokol, H.; Seksik, P.; Furet, J.P.; Firmesse, O.; Nion-Larmurier, I.; Beaugerie, L.; Cosnes, J.; Corthier, G.; Marteau, P.; Doré, J. Low Counts of Faecalibacterium prausnitzii in Colitis Microbiota. Inflamm. Bowel. Dis. 2009, 15, 1183–1189.
  67. Caudet, J.; Trelis, M.; Cifre, S.; Soriano, J.M.; Rico, H.; Merino-Torres, J.F. Interplay between Intestinal Bacterial Communities and Unicellular Parasites in a Morbidly Obese Population: A Neglected Trinomial. Nutrients 2022, 14, 3211.
  68. Yao, S.; Zhao, Z.; Wang, W.; Liu, X. Bifidobacterium Longum: Protection against Inflammatory Bowel Disease. J. Immunol. Res. 2021, 2021, 8030297.
  69. Alzate, J.F.; Toro-Londoño, M.; Cabarcas, F.; Garcia-Montoya, G.; Galvan-Diaz, A. Contrasting microbiota profiles observed in children carrying either Blastocystis spp. or the commensal amoebas Entamoeba coli or Endolimax nana. Sci. Rep. 2020, 10, 15354.
  70. Gotfred-Rasmussen, H.; Stensvold, C.R.; Ingham, A.C.; Johannesen, T.B.; Andersen, L.O.B.; Röser, D.; Nielsen, H.V. Impact of Metronidazole Treatment and Dientamoeba Fragilis Colonization on Gut Microbiota Diversity. J. Pediatr. Gastroenterol. Nutr. 2021, 73, 23–29.
  71. Freeman, C.D.; Klutman, N.E.; Lamp, K.C. Metronidazole. A therapeutic review and update. Drugs 1997, 54, 679–708.
  72. Morton, E.R.; Lynch, J.; Froment, A.; Lafosse, S.; Heyer, E.; Przeworski, M.; Blekhman, R.; Ségurel, L. Variation in Rural African Gut Microbiota Is Strongly Correlated with Colonization by Entamoeba and Subsistence. PLoS Genet. 2015, 11, e1005658.
  73. Chen, Y.; Yang, Y.; Gu, J. Clinical Implications of the Associations Between Intestinal Microbiome and Colorectal Cancer Progression. Cancer Manag. Res. 2020, 12, 4117–4128.
  74. Doumatey, A.P.; Adeyemo, A.; Zhou, J.; Lei, L.; Adebamowo, S.N.; Adebamowo, C.; Rotimi, C.N. Gut Microbiome Profiles Are Associated With Type 2 Diabetes in Urban Africans. Front. Cell. Infect. Microbiol. 2020, 10, 63.
  75. Charania, R.; Wade, B.E.; McNair, N.N.; Mead, J.R. Changes in the Microbiome of Cryptosporidium-Infected Mice Correlate to Differences in Susceptibility and Infection Levels. Microorganisms 2020, 8, 879.
  76. Deng, L.; Wojciech, L.; Png, C.W.; Koh, E.Y.; Aung, T.T.; Kioh, D.Y.Q.; Chan, E.C.Y.; Malleret, B.; Zhang, Y.; Peng, G.; et al. Experimental colonization with Blastocystis ST4 is associated with protective immune responses and modulation of gut microbiome in a DSS-induced colitis mouse model. Cell Mol. Life Sci. 2022, 79, 245.
  77. Blaak, E.E.; Canfora, E.E.; Theis, S.; Frost, G.; Groen, A.K.; Mithieux, G.; Nauta, A.; Scott, K.; Stahl, B.; van Harsselaar, J.; et al. Short chain fatty acids in human gut and metabolic health. Benef. Microbes 2020, 11, 411–455.
  78. Carretta, M.D.; Quiroga, J.; López, R.; Hidalgo, M.A.; Burgos, R.A. Participation of Short-Chain Fatty Acids and Their Receptors in Gut Inflammation and Colon Cancer. Front. Physiol. 2021, 12, 662739.
  79. Corrêa-Oliveira, R.; Fachi, J.L.; Vieira, A.; Sato, F.T.; Vinolo, M.A. Regulation of immune cell function by short-chain fatty acids. Clin. Transl. Immunol. 2016, 5, e73.
  80. Lim, M.X.; Png, C.W.; Tay, C.Y.; Teo, J.D.; Jiao, H.; Lehming, N.; Tan, K.S.; Zhang, Y. Differential regulation of proinflammatory cytokine expression by mitogen-activated protein kinases in macrophages in response to intestinal parasite infection. Infect. Immun. 2014, 82, 4789–4801.
  81. Siqueira-Neto, J.L.; Debnath, A.; McCall, L.I.; Bernatchez, J.A.; Ndao, M.; Reed, S.L.; Rosenthal, P.J. Cysteine proteases in protozoan parasites. PLoS Negl. Trop. Dis. 2018, 12, e0006512.
  82. Tan, P.; Li, X.; Shen, J.; Feng, Q. Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update. Front. Pharmacol. 2020, 11, 574533.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Academic Video Service
Feedback